Treatment of refractory post-esophagectomy anastomotic esophageal strictures using temporary fully covered esophageal metal stenting compared to repeated bougie dilation: results of a randomized controlled trial by Kappelle, W.F.W. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/205371
 
 
 
Please be advised that this information was generated on 2020-01-01 and may be subject to
change.
Introduction
Benign esophageal strictures are a challenging clinical problem
and may occur secondary to gastroesophageal reflux disease,
external beam radiation, caustic ingestion, or surgical anasto-
mosis following esophagectomy [1, 2]. A common cause of be-
nign strictures of the esophagus is development of anastomotic
strictures following resection of the distal esophagus and prox-
imal stomach for treatment of esophageal cancer [3, 4]. The
mainstay of management of benign esophageal strictures is
esophageal dilation. Several techniques for dilation exist and
the most commonly used ones are Savary-Gilliard bougie dila-
tion (BD) and through-the-scope (TTS) balloon dilation [5].
Treatment of refractory post-esophagectomy anastomotic
esophageal strictures using temporary fully covered esophageal
metal stenting compared to repeated bougie dilation: results
of a randomized controlled trial
Authors
W. F. Kappelle1, J. E. van Hooft2, M. C. W. Spaander3, F. P. Vleggaar1, M. J. Bruno3, F. Maluf-Filho4, A. Bogte1,
E. van Halsema2, P. D. Siersema1,5
Institutions
1 University Medical Center Utrecht, Utrecht, The
Netherlands
2 Academic Medical Center, Amsterdam, The Netherlands
3 Erasmus University Medical Center, Rotterdam, The
Netherlands
4 Instituto do Cancer do Estado de Sao Paulo, Sao Paulo,
Brazil
5 Radboud University Medical Center, Nijmegen, The
Netherlands
submitted 26.4.2018
accepted after revision 24.9.2018
Bibliography
DOI https://doi.org/10.1055/a-0777-1856 |
Endoscopy International Open 2019; 07: E178–E185
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 2364-3722
Corresponding author
Peter D. Siersema, MD, PhD, Dept. of Gastroenterology and
Hepatology, Radboud University Medical Center, Nijmegen,
The Netherlands
Fax: +31 10 465 8520
peter.siersema@radboudumc.nl
ABSTRACT
Background and study aims Fully covered self-expanding
metal stents (FCSEMS) provide an alternative to bougie dila-
tion (BD) for refractory benign esophageal strictures. Con-
trolled studies comparing temporary placement of FCSES to
repeated BD are not available.
Patients and methods Patients with refractory anasto-
motic esophageal strictures, dysphagia scores≥2, and two
to five prior BD were randomized to 8 weeks of FCSEMS or
to repeated BD. The primary endpoint was the number of
BD during the 12 months after baseline treatment.
Results Eighteen patients were included (male 67%, medi-
an age 66.5; 9 received metal stents, 9 received BD). Tech-
nical success rate of stent placement and stent removal was
100%. Recurrent dysphagia occurred in 13 patients (72%)
during follow-up. No significant difference was found be-
tween the stent and BD groups for mean number of BD dur-
ing follow-up (5.4 vs. 2.4, P=0.159), time to recurrent dys-
phagia (median 36 days vs. 33 days, Kaplan-Meier: P=
0.576) and frequency of reinterventions per month (medi-
an 0.3 vs. 0.2, P=0.283). Improvement in quality of life
score was greater in the stent group compared to the BD
group at month 12 (median 26% vs. 4%, P=0.011).
Conclusions The current data did not provide evidence for
a statistically significant difference between the two groups
in the number of BD during the 12 months after initial treat-
ment. Metal stenting offers greater improvement in quality
of life from baseline at 12 months compared to repeated BD
for patients with refractory anastomotic esophageal stric-
tures.
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While 80% to 90% of patients initially respond to dilation,
most patients require more than one session to reach adequate
dilation, and nearly 10% will experience a refractory or recur-
rent stricture despite repeated dilation [6]. Perforation is the
most serious complication of esophageal dilation, and carries a
mortality rate of approximately 20% [7]. The overall perfora-
tion rate has been reported to be 0.1% to 0.4%, but rates as
high as 1.9% have been reported with BD [8]. The rate of signif-
icant bleeding after dilation, likely the result of mucosal disrup-
tion caused by dilation, has been reported to be 0.4%. Further-
more, retrosternal pain is reported in 0% to 5% of cases after
dilation [9].
Adjuncts to management of difficult benign esophageal
strictures include steroid injection, cautery, and topical appli-
cation of the antiproliferative agent mitomycin C. Most recent-
ly, esophageal stenting techniques have been used in patients
with esophageal strictures. Options for stenting include non-
metal (plastic) expandable stents, biodegradable stents, and
self-expanding metal stents (SEMS) [6, 10–15]. Over the past
20 years, SEMS have become available in a wide variety of ma-
terials and configurations. Stainless steel and nitinol (an alloy of
nickel and titanium) are the most common materials used in
SEMS design, and the wire mesh construction of the stent can
be braided or woven [16]. SEMS are also available in uncovered
(bare) versions as well as versions that are partially covered (PC)
or fully covered (FC) with silicone membranes. PC and FCSEMS
are designed to reduce tissue ingrowth through the mesh of
the stent. As a result, the FCSEMS appear to allow for long-
term removability, thus permitting their use in both malignant
and benign disease [10, 12, 17].
Use of FCSEMS for management of postoperative complica-
tions following esophagectomy has not been well studied.
However, several studies have included small numbers of pa-
tients with refractory anastomotic esophageal strictures who
were treated with FCSEMS [18–21]. Results from these studies
have indicated that while FCSEMS are in place, generally over a
period of a few months, the patients experience a reduction in
dysphagia symptoms associated with anastomotic strictures,
but symptoms return shortly after the stent is removed in all
but 20% to 30% of patients. In addition, these studies report
frequent complications associated with esophageal stenting,
particularly stent migration and erosion of tissue surrounding
the stent. Our study adds to the literature a randomized com-
parison of anastomotic esophageal stricture treatment using
temporary placement of a FCSEMS to repeated BD.
Patients and methods
Study design
This was a prospective, multicenter, randomized, controlled,
open-label clinical trial. The study was conducted in the Nether-
lands and Brazil and was approved by the ethics committee of
the University Medical Center Utrecht, the Netherlands, and
thereafter by the ethics committees of all participating centers.
In Brazil, the study was also approved by the Brazilian regula-
tory Competent Authority prior to enrollment. All patients
provided written informed consent at the time of enrollment.
The study was conducted in accordance with the latest version
of the Declaration of Helsinki. The trial was sponsored by Bos-
ton Scientific Corporation and is registered at www.Clinical-
Trials.gov, number NCT01699542. All procedures were per-
formed by endoscopists with extensive experience with treat-
ment of esophageal diseases, including benign esophageal
strictures.
Patients
Patients with a refractory symptomatic esophagogastric ana-
stomotic stricture post-esophagectomy were enrolled at four
centers, three in the Netherlands and one in Brazil. Eligible pa-
tients were 18 years or older and had esophageal anastomotic
benign stricture post-esophagectomy (esophagogastric stric-
tures), which was performed at the same institution where pa-
tient enrollment and follow-up was planned; baseline Ogilvie
dysphagia scores of Grade 2 (ability to swallow semi-solid
foods), Grade 3 (ability to swallow liquids only), or Grade 4 (un-
able to swallow liquids) [22]; between two and five prior dila-
tions to at least 16mm in diameter (first dilation no more than
6 months and last dilation no more than 24 months post-eso-
phagectomy); a stricture unable to pass with a standard endo-
scope of approximately 9.8mm diameter, and were willing and
able to comply with study procedures and provide written in-
formed consents. Major exclusion criteria included strictures
within 2 cm of the upper esophageal sphincter, strictures more
than 5 cm in length, dysphagia related to a motility disorder,
non-anastomotic esophageal strictures, esophagocolonic stric-
tures, prior esophageal stent placement, and active erosive
esophagitis.
Procedures
Patients were randomized 1:1 to endoscopic BD or temporary
placement of a FCSEMS, the WallFlex Esophageal FC stent (Bos-
ton Scientific, Marlboro, Massachusetts, United States) which is
made of nitinol wires braided to form a cylindrical mesh. The
stent contains a flare at both ends to minimize risk of migra-
tion. A suture is threaded just on the proximal end and may be
used to remove or reposition the stent. Stent sizes were 18-mm
body diameter and 103-, 123-, or 153-mm length; or 23-mm
body diameter with 105-, 125-, or 155-mm length.
The WallFlex stent was chosen for this study because it is an
easy-to-place stent, even in inexperienced hands. Because it is
available in a fully-covered version, it is amenable for use for be-
nign indications. The stent has a good safety record with a low
risk of adverse events (AEs). Finally, the combination of radial
and axial force and the flexibility of the stent theoretically re-
duce the risk of stent migration [23].
Patients in the SEMS group were treated with a single
FCSEMS at time 0, with endoscopic imaging confirmation after
placement. FCSEMS were removed per protocol at 8 weeks (± 7
days) post-placement or sooner if complications occurred, at
the discretion of the treating physician and patient. After stent
removal, dilation for recurrence of dysphagia was repeated as
needed, and these dilation procedures were recorded until
end of study at 12 months after enrollment. The BD group re-
ceived dilations up to at least 16mm, in one to four dilation ses-
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sions, per standard treatment; the date of the last dilation ses-
sion was considered time 0, completion of the initial study
treatment. In cases of recurrent dysphagia in the BD group, di-
lation was repeated and recorded until 12 months after enroll-
ment.
Follow-up
After initial study treatment, all patients completed an in-per-
son or by-phone visit on Day 2, Week 2, and Months 1, 2, 3, 6,
9, and 12. In the SEMS group, the Month 2 visit coincided with
endoscopic removal of the FCSEMS. At each follow-up visit, in-
formation on AEs was collected, Quality of life (QoL) was eval-
uated per the EQ-5D-5 L questionnaire, a validated question-
naire for describing and valuing general health based on five di-
mensions including mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression [24]. A patient’s reported
pain and satisfaction with therapy was assessed using a 10-
point visual analog scale (VAS) and episodes of dysphagia (at
baseline, daily for the first month and weekly thereafter up to
12 months) were evaluated as recorded in the patient’s diary,
and endoscopic and/or fluoroscopic imaging was conducted in
the FCSEMS group at the discretion of the investigator. Each
subject was followed for 12 months post-initial study treat-
ment.
Endpoints
The primary endpoint was the number of dilation procedures
for management of dysphagia within 12 months following ini-
tial study treatment. Secondary endpoints included AEs related
to the device and/or procedure; technical stent placement suc-
cess, defined as the ability to deploy the stent in satisfactory
position across the stricture with a standard 9.-mm endoscope;
technical stent removal success, defined as the ability to re-
move the stent without complications; time to recurrence of
dysphagia, defined as inability to pass the stricture; stent mi-
gration with or without symptoms; number of reinterventions
within 12 months following the initial study treatment; dyspha-
gia scores throughout follow-up; patient report of pain and sa-
tisfaction with the therapy (by VAS); and change in QoL.
Sample size calculation
Based on prior experience of the senior investigator (PS), after
initial treatment with a SEMS, approximately half the patients
do not require dilation procedures for management of dyspha-
gia, and approximately half require one to three dilations in the
subsequent 12 months [2]. After initial treatment with BD, ap-
proximately 30% of patients need at most one dilation and ap-
proximately 70% of patients need two to four dilations in the
12-month period [5]. This yields an expected number of dila-
tions of 1.0 with standard deviation (SD) of 1.15 in the SEMS
group, and 2.3 with SD of 1.39 in the BD group. The hypothesis
of the study was superiority of the mean number of dilation
procedures in the SEMS group compared to the BD group, with
a margin of 1.30, 80% power and two-sided alpha of 0.05. Test-
ing this hypothesis required 20 patients per group. Adding 10%
of patients to compensate for potential attrition during follow-
up yielded the initial 44-patient enrollment goal. Due to slow
enrollment, the study was discontinued after 33 months when
18 patients had been enrolled and completed the 12-month
follow-up.
Randomization
Patients were randomized to a 1:1 ratio between the Stent Arm
(Group A) and BD Arm (Group B). Randomization was stratified
by clinical site using random block sizes of four. Randomization
sequence was created using SAS version 9.3 and executed at
the time of initial treatment by study staff at each participating
center. After a patient was enrolled and passed screening, site
staff referred to the randomization sequence to determine
treatment assignment. An electronic database was the primary
method to implement randomization with envelopes as a back-
up method. At the end of trial enrollment, a total of 18 patients
were randomized, with nine assigned to the Stent Group and
nine to the BD Group.
Statistical analyses
Baseline data (patient demographics and medical history) and
post-procedure information was summarized using descriptive
statistics (e. g., mean, standard deviation, number of data
points used) for continuous variables with normal distribution
or count variables, interquartile range for continuous variable
with non-normal distribution, and frequency tables for discrete
variables. A negative binomial model was used to compare the
primary endpoint and the number of dilation procedures for
management of dysphagia during 12-month follow-up be-
tween the BD and SEMS group. Univariate and multivariate a-
nalysis were performed per protocol to assess possible predic-
tors of the primary endpoint. Factors from the univariate model
with P≤0.20 were modeled multivariately using a stepwise pro-
cedure in a negative binomial model. The significance thresh-
olds for entry and exit into the model was set to P<0.10.
Change in overall QoL health score was analyzed using repeated
measures analysis.
Results
Participant flow
A total of 22 patients were assessed for eligibility, of whom four
were excluded for not meeting inclusion criteria (3 patients)
and investigative site error during enrollment (1 patient). Eigh-
teen patients were deemed eligible and were subsequently ran-
domized, as shown in ▶Fig. 1.
Baseline
Baseline (BL) characteristics were similar between the two
study groups (▶Table 1). Mean age was 67±7 years and 67%
of patients were male. Esophagectomy was transthoracic in
78 % (14/18) and transhiatal in 22% (4/18). Mean time from
esophagectomy to first dilation was 95±36 days. Mean stric-
ture length was 0.7 cm (range 0.3–1.5 cm), located at 21.6 ±
2.9 cm from the incisors. The SEMS group had lower baseline
QoL scores (median 65 vs. 80, P=0.021), but similar dysphagia
scores (median 2 vs. 2, P=0.206) and number of BDs up to 12
months prior to baseline treatment (mean 2 vs. 2.4, P=0.566).
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Assessed for eligibility (n = 22)
Randomized (n = 18)
Allocation
Enrollment
Excluded (n = 4)
▪ Not meeting inclusion criteria (n = 3)
▪ Declined to participate (n = 0)
▪ Other reasons (n = 1)
 ▪Investigative site error (n = 1)
Allocated to stent arm (n = 6)
▪ Received allocated intervention (n = 9)
▪ Did not receive allocated intervention
 (give reasons) (n = 0)
Allocated to Bougie dilation (n = 9)
▪ Received allocated intervention (n = 9)
▪ Did not receive allocated intervention
 (give reasons) (n = 0)
Follow-upLost follow-up (give reasons) (n = 0)
Discontinued intervention (give reasons) (n = 0)
Lost follow-up (give reasons) (n = 0)
Discontinued intervention (give reasons) (n = 0)
AnalysisAnalysed (n = 9)
▪ Excluded from analysis (give reasons) (n = 0)
Analysed (n = 9)
▪ Excluded from analysis (give reasons) (n = 0)
▶ Fig. 1 CONSORT diagram of study flow.
▶ Table 1 Demographics and baseline information.
BD SEMS P value1
Age 66.6 ±7.7 66.6 ±6.3 1.0
Male 66.7% (6/9) 66.7% (6/9) 1.0
Type of esophagectomy 0.577
Transthoracic 88.9% (8/9) 66.7% (6/9)
Transhiatal 11.1% (1/9) 33.3% (3/9)
Max dilation (second dilation) (mm) 15.9 ±2.0 (9) 16.4 ±0.9 (9) 0.450
Dysphagia score2 2.0 (2.0, 2.0) 2.0 (2.0, 3.0) 0.206
Dysphagia score = 2 100% (9/9) 66.7% (6/9) 0.206
Dysphagia score > 2 0.0% (0/9) 33.3% (3/9) 0.206
Number of pretreatment dilations 2.4 ±1.0 2.0 ±0.0 0.566
Quality of life overall health score 80.0 (70.0, 80.0) 65.0 (50.0, 70.0) 0.021
BD, bougie dilation; SEMS, self-expanding metal stents. Treatment group is per randomization.
1 P values calculated from t-test for continuous variable with normal distribution, Wilcoxon test for continuous variable with non-normal distribution, negative
binomial models for count variable, and Fisher’s exact for binary variable.
2 Median (IQR) presented for continuous variables with non-normal distribution.
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Initial treatment
Nine FCSEMS were placed, seven patients received an 18-mm
FCSEMS with a length of 103mm and two patients received a
23-mm FCSEMS with a length of 105mm. Technical placement
and removal success in the SEMS group was 100%. SEMS were
removed by retrieval of the suture at the proximal end of the
SEMS in 67% of patients (6/9) and from the stomach in 33% of
patients (3/9). Two patients required early removal due to
symptomatic stent migration.
Among the nine BD patients, six had a single dilation for ini-
tial treatment (16mm for 3 patients, 17mm for 1 patient and
18mm for 2 patients), two patients had two dilation sessions
(14mm followed by 16mm after 15 days in 1 patient and 15
mm followed by 17mm after 16 days in 1 patient), and one pa-
tient had three dilation sessions (14mm followed by 16mm
after 7 days and 18mm after 8 days).
Treatment of recurrent dysphagia
Post-treatment dilations and reinterventions are listed in ▶Ta-
ble2. Dysphagia was the cause of reintervention in 89% (23/26)
of the BD group and 98% (49/50) of the SEMS group. In the BD
group, other causes for reintervention are as followings: one
patient had a gastroscopy to check for recurrent stenosis, one
patient had odynophagia and a third patient reported com-
plaints with passing food but a slight stricture could be passed
with a diagnostic scope (approx. 9.8-mm diameter) and hence
this was not qualified as dysphagia caused by the stricture. In
the SEMS group, one patient had a reintervention due to pleuri-
tic carcinomatosa of the right lung and had a chest tube into
the right pleura and pleurodesis. The mean number of post-
treatment dilations for dysphagia was not different between
the groups (2.4 for the BD group; 5.4 for the SEMS group; P=
0.159). A Kaplan-Meier analysis of time to first recurrence after
initial treatment for the BD group and after removal for the
SEMS group demonstrated no difference between groups (P=
0.576) (▶Fig. 2). Median time to recurrence of dysphagia after
treatment was 33 days for the BD group and 36 days for the
SEMS group. The most common reason for recurrent dysphagia
was stricture recurrence. The most common reintervention was
BD, 92% of the interventions in the BD group and 94% in the
SEMS group. Both groups experienced similar reductions in fre-
quency of dilation (calculated as number of dilations divided by
duration from first to last dilation) after the initial study treat-
ment (P=0.931). In the BD group, median frequency of dilation
▶ Table 2 Post-initial treatment dilations and reinterventions.
BD SEMS P value1
Number of post-dilations due to dysphagia through 12 months 2.4 ± 2.5 5.4 ±5.4 0.159
Number of post-dilations through 12 months 2.7 ± 2.6 5.4 ±5.4 0.183
Frequency of dilation per month post-treatment2,3 0.2 (0.1, 0.3) 0.3 (0.2, 1.1) 0.283
Total number of reinterventions 2.9 ± 2.7 5.6 ±5.3 0.168
Time to first recurrence of dysphagia3 33 (21, 33) 36 (24, 71) 0.576
Reintervention due to dysphagia 88.5% (23/26) 98.0% (49/50) 0.113
Reason for dysphagia recurrence
Stent migration 0.0% (0/23) 6.1% (2/33) 0.507
New stricture formation 4.3% (1/23) 0.0% (0/33) 0.411
Stricture recurrence 95.7% (22/23) 87.9% (29/33) 0.639
Other 0.0% (0/23) 6.1% (2/33)4 0.507
Type of Reintervention
Study stent removed 0.0% (0/26) 4.0% (2/50) 0.544
Bougie dilation 96.2% (24/26) 94.0% (47/50) 1.0
Balloon dilation 0.0% (0/26) 4.0% (2/50) 0.544
Other 7.7% (2/26) 20.0% (10/50)5 0.202
BD, bougie dilation; SEMS, self-expanding metal stents
Treatment group is per randomization.
KM estimated median (IQR) presented for time to event variables.
1 P values calculated from Wilcoxon test for continuous variable with non-normal distribution, negative binomial models for count variable, fisher’s exact for binary
variable, and log-rank test for time to event variable.
2 Defined as time 0 to last follow-up or end of study for BD and stent removal to last follow-up or end of study for SEMS
3 Median (IQR) presented for continuous variables with non-normal distribution and
4 One patient experienced two incidences of recurrent dysphagia; cause unknown
5 Other types of reintervention are: gastroscopy to check for recurrent stenosis (1) and gastroscopy performed but no stenosis (1) for BD and needle knife (9) and
Chest tube into right pleura and pleurodesis (1) for SEMS.
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decreased from 2.7 before study treatment to 0.2 interventions
per month after study treatment. In the SEMS group, the medi-
an frequency decreased from 2.9 to 0.3.
Multivariate analysis
A multivariate analysis identified location of anastomotic stric-
ture, age and treatment modality – SEMS or BD – as predictors
of the number of reinterventions due to dysphagia (▶Table 3).
Age was not a significant predictor at the 0.05 level when ad-
justing for other covariates. Multivariate analysis demonstrated
that with each centimeter increase of distance from the incisors
to the stricture, the number of reinterventions for dysphagia
during 12 months after the initial treatment decreased by 32%
(P=0.006).
Patient-reported outcomes
Pain by VAS in the SEMS group was generally low, with median
ranging from 0at baseline to a maximum of 3 at Day 2, and a
return to low levels (median 0) at Day 14 which remained low
during follow-up. In the BD group, pain levels were consistently
low (median 0) during follow-up. Patient satisfaction with treat-
ment was similar between the groups (SEMS median ranging
from 8 to 9.5; BD median ranging from 8 to 10). The repeated
measures analysis on QoL overall health score change suggests
a significant difference between SEMS group and the BD group
(P=0.043). As seen in ▶Fig. 3, patients in the SEMS group
seemed to experience a greater QoL improvement following in-
itial study treatment compared with the BD group. It is possible
that the significant difference in baseline scores between the
two groups may have contributed to the greater improvement
in the SEMS group. In other words, the SEMS group improved
more because there was more room for improvement in this
group.Additionally, when interpreting the QoL improvement,
one should consider the under-enrollment and the small sam-
ple size and the similar satisfaction scores between the two
groups. It is possible that patients were equally satisfied with
the treatment but SEMS patients experienced higher improve-
ment in overall QoL due to fewer procedures to manage dys-
phagia while the stent was in place. Details of patient-reported
outcomes, including VAS pain score and patient satisfaction
score, are shown in ▶Fig. 4 and ▶Fig. 5.
Adverse events
A total of eight AEss were related to either the procedure or the
device, of which seven were non-serious and one serious. In the
SEMS group, one patient experienced aspiration during FCSEMS
removal (serious), one experienced recurrent dysphagia due to
stent migration, one had stent-related gastroesophageal re-
flux, one had foreign body sensation and retching due to for-
eign body sensation (both related to stent), one experienced
thoracic pain and cervical pain during FCSEMS placement pro-
cedure, and one patient had epigastric pain after FCSEMS re-
moval.
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▶ Fig. 2 Kaplan-Meier analysis of time to first recurrence. The start
time of the 12-month follow-up period for the bougie dilation (BD)
group was the same as time 0, which is defined as the end of the
initial treatment period. However, for the stent (SEMS) group, the
start time of follow-up was the time of stent removal rather than
stent placement.
▶ Table 3 Multivariate analysis of number of reinterventions due to
dysphagia.
Predictor Rate ratio
95% CI
P value1
SEMS vs. BD 2.4
(1.0, 5.7)
0.053
Location of anastomotic stricture 0.7
(0.5, 0.9)
0.006
BD, bougie dilation; SEMS, self-expanding metal stent
1 Negative binomial model is used.
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▶ Fig. 3 Change from baseline in quality of life (QoL) scores using
the EQ-5D-5 L questionnaire. The repeated measures analysis
showed a significant effect of treatment on overall health score
change (P=0.043) as well as a significant effect of time (P=0.028).
No significant interaction effect between treatment and time was
found.
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Discussion
The current study confirmed that FCSEMS placement is a tech-
nically feasible and a clinically effective treatment for benign
refractory anastomotic strictures after esophagectomy during
FCSEMS indwell, including greater QoL improvement during
FCSEMS treatment compared with continued BD. However, the
number of dilations required in the 12 months after treatment
were comparable between the two groups. Patients’ reports of
pain and satisfaction were similar between the groups.
The study failed to confirm our initial hypothesis, namely
that placement of a FCSEMS would reduce the number of dila-
tions over a follow-up time of 12 months after initial treatment.
Several factors may have contributed to this outcome. First, the
sample size was smaller than intended, thus complicating de-
tection of small differences between the two methods. Based
on the 18 subjects randomized, the power to detect the prede-
fined relevant difference in the primary outcome was low and
consequently the chance of detecting a true effect may be re-
duced. Similarly, multivariate analysis results and QoL results
should be interpreted with caution. Due to slow enrollment
over 33 months, it was decided to discontinue enrollment be-
fore the predefined required number of patients was included.
The main reason for slow enrollment is that patients tend to be
more willing to receive standard of care than to try out a new
treatment, therefore, one inclusion criterion was relaxed,
namely the number of dilations to reach 16mm in diameter
since esophagectomy. Originally this was two dilations, but
was expanded to allowing two to five dilations. Another limita-
tion was that time 0 started at the last dilation session for the
BD group and at stent placement for the SEMS group, because
that time point reflects the time at which the stricture is first
dilated to the largest diameter. That, however, led to the pa-
tients in the SEMS group having a 2-month shorter window to
document potential recurrence of dysphagia during 12 months
of follow-up after time 0. To adjust for this issue, the Kaplan
Meier analysis (▶Fig. 2) was conducted starting at the time of
stent removal for the SEMS group and at the time of the last di-
lation for the BD group.
Other limitations of the study include lack of data on details
on the anastomotic technique and that the caliber of stricture
was not evaluated by barium study. Gastroesophageal reflux
disease (GERD) is a common occurrence in esophagectomy pa-
tients and may contribute to esophageal pathology. In future
studies, the potential role of possible associated GERD should
be considered.
In addition, there were no clear criteria for dilation at the
time of recurrence of dysphagia in the study. Some patients re-
ceived reintervention to manage dysphagia without an ob-
served increase in dysphagia score.
In the current study, the stent was removed after 8 weeks to
avoid tissue overgrowth with new stricture formation as a re-
sult. During the time that the stent was in place, dilations for
dysphagia were avoided; after removal of the stent, the median
number of episodes of dysphagia requiring intervention in-
creased. These findings suggest that stent placement for be-
nign strictures is effective, but only as long as the stent is in
place. Its effect is not sustained once the stent has been re-
moved. Some anastomotic strictures are highly refractory due
to ongoing ischemia leading to recurrent fibrosis.
The number of related AEs was higher in the SEMS group.
Based on literature and our own experience, we see no reason
to suspect a direct causal relationship in the finding of in-
creased number of related events, and instead believe this to
be an artifact of the small sample size.
Despite not meeting the primary endpoint, patients in the
SEMS group experienced a higher QoL improvement from base-
line compared with the BD group, and the differences between
two groups were significant at Months 1 and 2 as well as toward
the end of the follow-up (at Months 9 and 12). Note that QoL
score at baseline in the SEMS group was significantly lower
than in the BD group. To account for baseline scores, QoL score
change from baseline in percentage was calculated instead of
the raw score. The peak improvement of the QoL in the SEMS
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group occurred at the time of stent removal (8 weeks). Both
groups had decreased frequency of interventions for dysphagia
during the study. Larger studies are needed to evaluate the re-
current dysphagia rate for FCSEMS vs. standard dilation in pa-
tients with refractory anastomotic strictures. Longer-term utili-
zation of FCSEMS and outcome measures comparing interven-
tions during the time of stenting only versus a standard dilation
group would be relevant outcome measures for subsequent
studies.
Conclusion
It can be concluded that in the current study, no significant dif-
ference was found between SEMS placement and repeat BD
with regard to the number of BDs thereafter. Nevertheless,
temporary FCSEMS indwell may offer reduced treatment bur-
den as long as the stent remains in place and offers similar (if
not greater) QoL improvement from baseline sustained for 12
months compared to repeat BD for patients with refractory
anastomotic esophageal strictures. In addition, biodegradable
stents could be considered as a patient-friendly alternative for
FCSEMS placement, as stent removal is avoided.
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